Biomarkers in Alzheimer’s disease: past, present and future

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34(7),939–944 (1984).▪ Indicates the importance of early diagnosis of Alzheimer’s disease (AD) and presents the first notion of appropriate and realistic clinical applications.
  Medline CASGoogle Scholar
• 2  Dubois B, Feldman HH, Jacova C et al.: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6(8),734–746 (2007).
  MedlineGoogle Scholar
• 3  Swets JA: Measuring the accuracy of diagnostic systems. Science240(4857),1285–1293 (1988).
  Medline CASGoogle Scholar
• 4  Evans DA, Funkenstein HH, Albert MS et al.: Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA262(18),2551–2556 (1989).
  Medline CASGoogle Scholar
• 5  Lerner AJ, Friedland RP, Whitehouse PJ: Uses of biological markers. Alzheimer Dis. Assoc. Disord.6(4),197–200 (1992).
  Medline CASGoogle Scholar
• 6  Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC: Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr. Alzheimer Res.6(4),347–361 (2009).
  Medline CASGoogle Scholar
• 7  Landau SM, Harvey D, Madison CM et al.: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging (2010) (Epub ahead of print).
  Google Scholar
• 8  Leow AD, Yanovsky I, Parikshak N et al.: Alzheimer’s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage45(3),645–655 (2009).
  MedlineGoogle Scholar
• 9  Querbes O, Aubry F, Pariente J et al.: Early diagnosis of Alzheimer’s disease using cortical thickness: impact of cognitive reserve. Brain132(Pt 8),2036–2047 (2009).
  MedlineGoogle Scholar
• 10  Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res.12(3),189–198 (1975).
  Medline CASGoogle Scholar
• 11  Mohs RC, Cohen L: Alzheimer’s Disease Assessment Scale (ADAS). Psychopharmacol. Bull.24(4),627–628 (1988).
  Medline CASGoogle Scholar
• 12  Ray S, Britschgi M, Herbert C et al.: Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11),1359–1362 (2007).
  Medline CASGoogle Scholar
• 13  Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580),353–356 (2002).
  Medline CASGoogle Scholar
• 14  Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA: Phosphorylated tau: toxic, protective, or none of the above. J. Alzheimers Dis.14(4),377–383 (2008).
  MedlineGoogle Scholar
• 15  Brouwers N, Sleegers K, Van Broeckhoven C: Molecular genetics of Alzheimer’s disease: an update. Ann. Med.40(8),562–583 (2008).
  Medline CASGoogle Scholar
• 16  Martinez-Garcia A, Aldudo J, Recuero M et al.: Presenilin 1 polymorphism associated with Alzheimer’s disease in apolipoprotein ε4 carriers. Dement. Geriatr. Cogn. Disord.26(5),440–444 (2008).
  Medline CASGoogle Scholar
• 17  McShea A, Lee HG, Petersen RB et al.: Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim. Biophys. Acta1772,467–472 (2007).
  Medline CASGoogle Scholar
• 18  Moreira PI, Santos MS, Oliveira CR et al.: Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol. Disord. Drug Targets7(1),3–10 (2008).
  Medline CASGoogle Scholar
• 19  Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X: The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J. Neurochem.109(Suppl. 1),153–159 (2009).
  Medline CASGoogle Scholar
• 20  Smith MA: Alzheimer disease. Int. Rev. Neurobiol.42,1–54 (1998).
  Medline CASGoogle Scholar
• 21  Roychaudhuri R, Yang M, Hoshi MM, Teplow DB: Amyloid β-protein assembly and Alzheimer disease. J. Biol. Chem.284(8),4749–4753 (2009).
  Medline CASGoogle Scholar
• 22  Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Amyloid β: the alternate hypothesis. Curr. Alzheimer Res.3(1),75–80 (2006).▪▪ Exemplifies our position on the role played by amyloid-β (Aβ) in the pathogensis of AD. That is, Aβ is secondary in the cascade of neurodegeneration that yields AD.
  Medline CASGoogle Scholar
• 23  Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA: Neuropathology of Alzheimer disease: pathogenomonic but not pathogenic. Acta Neuropathol. (Berl.)111(6),503–509 (2006).
  MedlineGoogle Scholar
• 24  Lee HG, Casadesus G, Zhu X, Joseph JA, Perry G, Smith MA: Perspectives on the amyloid-β cascade hypothesis. J. Alzheimers Dis.6(2),137–145 (2004).
  Medline CASGoogle Scholar
• 25  Sousa MM, Saraiva MJ: Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog. Neurobiol.71(5),385–400 (2003).
  Medline CASGoogle Scholar
• 26  Selkoe DJ: Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimers Dis.3(1),75–80 (2001).
  Medline CASGoogle Scholar
• 27  Greenberg SM, Koo EH, Selkoe DJ, Qiu WQ, Kosik KS: Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. Natl Acad. Sci. USA91(15),7104–7108 (1994).
  Medline CASGoogle Scholar
• 28  Clark CM, Karlawish JH: Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann. Intern. Med.138(5),400–410 (2003).
  MedlineGoogle Scholar
• 29  Craft JM, Watterson DM, Hirsch E, Van Eldik LJ: Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid. J. Neuroinflammation2,15 (2005).
  MedlineGoogle Scholar
• 30  Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P: Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol.37(7),943–948 (2002).▪▪ Presents the challenges previously associated with utilizing serum levels of Aβ for disease diagnosis.
  Medline CASGoogle Scholar
• 31  Du Y, Dodel R, Hampel H et al.: Reduced levels of amyloid β-peptide antibody in Alzheimer disease. Neurology57(5),801–805 (2001).
  Medline CASGoogle Scholar
• 32  Mruthinti S, Buccafusco JJ, Hill WD et al.: Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol. Aging25(8),1023–1032 (2004).
  Medline CASGoogle Scholar
• 33  Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ: Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem.271(51),32916–32922 (1996).
  Medline CASGoogle Scholar
• 34  Sagare A, Deane R, Bell RD et al.: Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med.13(9),1029–1031 (2007).
  Medline CASGoogle Scholar
• 35  Fullwood NJ, Hayashi Y, Allsop D: Plasma amyloid-β concentrations in Alzheimer’s disease: an alternative hypothesis. Lancet Neurol.5(12),1000–1001; author reply 1002–1003 (2006).
  MedlineGoogle Scholar
• 36  Oh ES, Troncoso JC, Fangmark Tucker SM: Maximizing the potential of plasma amyloid-β as a diagnostic biomarker for Alzheimer’s disease. Neuromolecular Med.10(3),195–207 (2008).
  Medline CASGoogle Scholar
• 37  Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx1(2),213–225 (2004).
  MedlineGoogle Scholar
• 38  Schenk D, Barbour R, Dunn W et al.: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740),173–177 (1999).
  Medline CASGoogle Scholar
• 39  Wilcock DM, Gordon MN, Ugen KE et al.: Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol.20(11),731–736 (2001).
  Medline CASGoogle Scholar
• 40  Gustaw KA, Garrett MR, Lee HG et al.: Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J. Neurochem.106(3),1350–1356 (2008).▪▪ Introduces our novel method of antibody–antigen dissociation for serum diagnosis of AD.
  Medline CASGoogle Scholar
• 41  Li Q, Cao C, Chackerian B et al.: Overcoming antigen masking of anti-amyloid-β antibodies reveals breaking of B cell tolerance by virus-like particles in amyloid-β immunized amyloid precursor protein transgenic mice. BMC Neurosci.5,21 (2004).
  Medline CASGoogle Scholar
• 42  Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ et al.: Dissociated amyloid-β antibody levels during the progression of Alzheimer’s disease: a population-based study. Exp. Gerontol.45,47–52 (2010).
  Medline CASGoogle Scholar
• 43  Ida N, Hartmann T, Pantel J et al.: Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J. Biol. Chem.271(37),22908–22914 (1996).
  Medline CASGoogle Scholar
• 44  Quesada JJ, Ferrucci L, Calvani D, Valente C, Salani B, Bavazzano A: Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older population. Aging (Milano)9(3),175–179 (1997).
  Medline CASGoogle Scholar
• 45  Iqbal K, Zaidi T, Thompson CH, Merz PA, Wisniewski HM: Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol. (Berl.)62(3),167–177 (1984).
  Medline CASGoogle Scholar
• 46  Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA83(13),4913–4917 (1986).
  Medline CASGoogle Scholar
• 47  Lee HG, Perry G, Moreira PI et al.: Tau phosphorylation in Alzheimer’s disease: pathogen or protector? Trends Mol. Med.11(4),164–169 (2005).
  Medline CASGoogle Scholar
• 48  Alonso AC, Grundke-Iqbal I, Iqbal K: Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med.2(7),783–787 (1996).
  Medline CASGoogle Scholar
• 49  Cash AD, Aliev G, Siedlak SL et al.: Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation. Am. J. Pathol.162(5),1623–1627 (2003).
  Medline CASGoogle Scholar
• 50  Brion JP, Passarier H, Nunez J, Flament-Durand J: Immunologic determinants of tau protein are present in neurofibrillary tangles of Alzheimer’s disease. Arch. Biol.95,229–235 (1985).
  Google Scholar
• 51  Kanemaru K, Takio K, Miura R, Titani K, Ihara Y: Fetal-type phosphorylation of the tau in paired helical filaments. J. Neurochem.58(5),1667–1675 (1992).
  Medline CASGoogle Scholar
• 52  Goedert M, Jakes R, Crowther RA et al.: The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc. Natl Acad. Sci. USA90(11),5066–5070 (1993).
  Medline CASGoogle Scholar
• 53  Pope WB, Lambert MP, Leypold B et al.: Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. Exp. Neurol.126(2),185–194 (1994).
  Medline CASGoogle Scholar
• 54  Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK: Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer’s disease. Neuroscience68(1),5–18 (1995).
  Medline CASGoogle Scholar
• 55  Vincent I, Rosado M, Davies P: Mitotic mechanisms in Alzheimer’s disease? J. Cell Biol.132(3),413–425 (1996).
  Medline CASGoogle Scholar
• 56  Ledesma MD, Correas I, Avila J, Diaz-Nido J: Implication of brain Cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer’s disease. FEBS Lett.308(2),218–224 (1992).
  Medline CASGoogle Scholar
• 57  Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E: Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett.336(3),417–424 (1993).
  Medline CASGoogle Scholar
• 58  McShea A, Wahl AF, Smith MA: Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses52(6),525–527 (1999).
  Medline CASGoogle Scholar
• 59  Zhu X, Rottkamp CA, Raina AK et al.: Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease. Neurobiol. Aging21(6),807–813 (2000).
  Medline CASGoogle Scholar
• 60  Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, Smith MA: Cyclin’ toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J. Neurosci. Res.61(2),128–133 (2000).
  Medline CASGoogle Scholar
• 61  Hampel H, Broich K, Hoessler Y, Pantel J: Biological markers for early detection and pharmacological treatment of Alzheimer’s disease. Dialogues Clin. Neurosci.11(2),141–157 (2009).▪ Provides a thorough overview on the current possibility for early detection and diagnosis of AD. Discusses the difficulty of such a diagnosis and demonstrates the value of our findings.
  MedlineGoogle Scholar
• 62  Heckmann JM, Low WC, de Villiers C et al.: Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer’s disease. Brain127(Pt 1),133–142 (2004).
  MedlineGoogle Scholar
• 63  Wong PC, Zheng H, Chen H et al.: Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature387(6630),288–292 (1997).
  Medline CASGoogle Scholar
• 64  Struhl G, Greenwald I: Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature398(6727),522–525 (1999).
  Medline CASGoogle Scholar
• 65  Ye Y, Lukinova N, Fortini ME: Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants. Nature398(6727),525–529 (1999).
  Medline CASGoogle Scholar
• 66  Wodarz A, Nusse R: Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol.14,59–88 (1998).
  Medline CASGoogle Scholar
• 67  Polakis P: The oncogenic activation of β-catenin. Curr. Opin. Genet. Dev.9(1),15–21 (1999).
  Medline CASGoogle Scholar
• 68  Janicki SM, Monteiro MJ: Presenilin overexpression arrests cells in the G₁ phase of the cell cycle. Arrest potentiated by the Alzheimer’s disease PS2(N141I)mutant. Am. J. Pathol.155(1),135–144 (1999).
  Medline CASGoogle Scholar
• 69  Mattson MP, Guo Q, Furukawa K, Pedersen WA: Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer’s disease. J. Neurochem.70(1),1–14 (1998).
  Medline CASGoogle Scholar
• 70  Lindwall G, Cole RD: Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem.259(8),5301–5305 (1984).
  Medline CASGoogle Scholar
• 71  Wolozin B, Iwasaki K, Vito P et al.: Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science274(5293),1710–1713 (1996).
  Medline CASGoogle Scholar
• 72  Park DS, Morris EJ, Padmanabhan J, Shelanski ML, Geller HM, Greene LA: Cyclin-dependent kinases participate in death of neurons evoked by DNA-damaging agents. J. Cell Biol.143(2),457–467 (1998).
  Medline CASGoogle Scholar
• 73  Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS: Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in β-amyloid-induced neuronal death. J. Biol. Chem.274(27),19011–19016 (1999).
  Medline CASGoogle Scholar
• 74  Carter DB: The interaction of amyloid-β with ApoE. Subcell. Biochem.38,255–272 (2005).
  Medline CASGoogle Scholar
• 75  Farrer LA, Cupples LA, Haines JL et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278(16),1349–1356 (1997).
  Medline CASGoogle Scholar
• 76  Van Duijn CM, Clayton DG, Chandra V et al.: Interaction between genetic and environmental risk factors for Alzheimer’s disease: a reanalysis of case–control studies. EURODEM Risk Factors Research Group. Genet. Epidemiol.11(6),539–551 (1994).
  Medline CASGoogle Scholar
• 77  Potkin SG, Guffanti G, Lakatos A et al.: Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS ONE4(8),e6501 (2009).
  MedlineGoogle Scholar
• 78  Markesbery WR: Oxidative stress hypothesis in Alzheimer’s disease. Free Radic. Biol. Med.23(1),134–147 (1997).
  Medline CASGoogle Scholar
• 79  Barni S, Sciola L, Spano A, Pippia P: Static cytofluorometry and fluorescence morphology of mitochondria and DNA in proliferating fibroblasts. Biotech. Histochem.71(2),66–70 (1996).
  Medline CASGoogle Scholar
• 80  Hirai K, Aliev G, Nunomura A et al.: Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci.21(9),3017–3023 (2001).
  Medline CASGoogle Scholar
• 81  Sousa M, Barros A, Silva J, Tesarik J: Developmental changes in calcium content of ultrastructurally distinct subcellular compartments of preimplantation human embryos. Mol. Hum. Reprod.3(2),83–90 (1997).
  Medline CASGoogle Scholar
• 82  Zhu X, Lee HG, Perry G, Smith MA: Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta1772(4),494–502 (2007).
  Medline CASGoogle Scholar
• 83  Ferrer I, Blanco R, Carmona M, Puig B: Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural Transm.108(12),1397–1415 (2001).
  Medline CASGoogle Scholar
• 84  Zhu X, Lee HG, Raina AK, Perry G, Smith MA: The role of mitogen-activated protein kinase pathways in Alzheimer’s disease. Neurosignals11(5),270–281 (2002).
  Medline CASGoogle Scholar
• 85  Zhang L, Jope RS: Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. Neurobiol. Aging20(3),271–278 (1999).
  Medline CASGoogle Scholar
• 86  Smith MA, Sayre LM, Monnier VM, Perry G: Radical AGEing in Alzheimer’s disease. Trends Neurosci.18(4),172–176 (1995).
  Medline CASGoogle Scholar
• 87  Luo Y, Bond JD, Ingram VM: Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proc. Natl Acad. Sci. USA94(18),9705–9710 (1997).
  Medline CASGoogle Scholar
• 88  Takeda A, Perry G, Abraham NG et al.: Overexpression of heme oxygenase in neuronal cells, the possible interaction with tau. J. Biol. Chem.275(8),5395–5399 (2000).
  Medline CASGoogle Scholar
• 89  Zhu X, Raina AK, Perry G, Smith MA: Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol.3(4),219–226 (2004).
  Medline CASGoogle Scholar
• 90  Zhu X, Castellani RJ, Takeda A et al.: Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis. Mech. Ageing Dev.123(1),39–46 (2001).
  Medline CASGoogle Scholar
• 91  Nagy ZS, Smith MZ, Esiri MM, Barnetson L, Smith AD: Hyperhomocysteinaemia in Alzheimer’s disease and expression of cell cycle markers in the brain. J. Neurol. Neurosurg. Psychiatry69(4),565–566 (2000).
  Medline CASGoogle Scholar
• 92  Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science274(5293),1664–1672 (1996).
  Medline CASGoogle Scholar
• 93  Padmanabhan J, Park DS, Greene LA, Shelanski ML: Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J. Neurosci.19(20),8747–8756 (1999).
  Medline CASGoogle Scholar
• 94  Gartner U, Holzer M, Arendt T: Elevated expression of p21ras is an early event in Alzheimer’s disease and precedes neurofibrillary degeneration. Neuroscience91(1),1–5 (1999).
  Medline CASGoogle Scholar
• 95  Lee HG, Casadesus G, Nunomura A et al.: The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse. Am. J. Pathol.174(3),891–897 (2009).
  Medline CASGoogle Scholar
• 96  McShea A, Lee HG, Petersen RB et al.: Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim. Biophys. Acta1772(4),467–472 (2007).
  Medline CASGoogle Scholar
• 97  Ledoux S, Rebai N, Dagenais A et al.: Amyloid precursor protein in peripheral mononuclear cells is up-regulated with cell activation. J. Immunol.150(12),5566–5575 (1993).
  Medline CASGoogle Scholar
• 98  Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P: Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J.13(5),1114–1122 (1994).
  Medline CASGoogle Scholar
• 99  Whitson JS, Selkoe DJ, Cotman CW: Amyloid-β protein enhances the survival of hippocampal neurons in vitro. Science243(4897),1488–1490 (1989).
  Medline CASGoogle Scholar
• 100  McDonald DR, Bamberger ME, Combs CK, Landreth GE: β-amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci.18(12),4451–4460 (1998).
  Medline CASGoogle Scholar
• 101  Rapoport M, Ferreira A: PD98059 prevents neurite degeneration induced by fibrillar β-amyloid in mature hippocampal neurons. J. Neurochem.74(1),125–133 (2000).
  Medline CASGoogle Scholar
• 102  Busser J, Geldmacher DS, Herrup K: Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer’s disease brain. J. Neurosci.18,2801–2807 (1998).
  Medline CASGoogle Scholar
• 103  Koliatsos VE: Biological therapies for Alzheimer’s disease: focus on trophic factors. Crit. Rev. Neurobiol.10(2),205–238 (1996).
  Medline CASGoogle Scholar
• 104  Stopa EG, Gonzalez AM, Chorsky R et al.: Basic fibroblast growth factor in Alzheimer’s disease. Biochem. Biophys. Res. Commun.171(2),690–696 (1990).
  Medline CASGoogle Scholar
• 105  Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J: Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer’s disease. J. Neurosci.13(6),2540–2550 (1993).
  Medline CASGoogle Scholar
• 106  van der Wal EA, Gomez-Pinilla F, Cotman CW: Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport4(1),69–72 (1993).
  Medline CASGoogle Scholar
• 107  Lesort M, Johnson GV: Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience99(2),305–316 (2000).
  Medline CASGoogle Scholar
• 108  Russell JW, Windebank AJ, Schenone A, Feldman EL: Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. J. Neurobiol.36(4),455–467 (1998).
  Medline CASGoogle Scholar
• 109  Raina AK, Hochman A, Zhu X et al.: Abortive apoptosis in Alzheimer’s disease. Acta Neuropathol. (Berl).101(4),305–310 (2001).
  Medline CASGoogle Scholar
• 110  Yang Y, Mufson EJ, Herrup K: Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J. Neurosci.23(7),2557–2563 (2003).
  Medline CASGoogle Scholar
• 111  Spremo-Potparevic B, Zivkovic L, Djelic N, Plecas-Solarovic B, Smith MA, Bajic V: Premature centromere division of the X chromosome in neurons in Alzheimer’s disease. J. Neurochem.106(5),2218–2223 (2008).
  Medline CASGoogle Scholar
• 112  Bowser R, Smith MA: Cell cycle proteins in Alzheimer’s disease: plenty of wheels but no cycle. J. Alzheimers Dis.4(3),249–254 (2002).
  Medline CASGoogle Scholar